Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors-towards individualized tumor treatment?

Neuro-Oncology

Volumn 12, Issue 5, 2010, Pages 490-499

  Ramirez, Carole ^a,b   Bowman, Clive ^c   Maurage, Claude Alain ^a   Dubois, François ^a   Blond, Serge ^a   Porchet, Nicole ^a,b   Escande, Fabienne ^a  

^a UNIV LILLE   (France)

^b JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^c UNIVERSITY OF READING   (United Kingdom)

Author keywords

Chemosensitivity; Gliomas; Loss of heterozygosity; Prognosis; Prospective study

Indexed keywords

LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; MICROSATELLITE DNA;

ADULT; AGED; ALLELE; ARTICLE; CANCER GROWTH; CHROMOSOMAL LOCALIZATION; CHROMOSOME 10Q; CHROMOSOME 19Q; CHROMOSOME 1P; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; BRAIN TUMOR; CHROMOSOME 1; CHROMOSOME 10; CHROMOSOME 19; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETICS; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PERSONALIZED MEDICINE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 19; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; KAPLAN-MEIERS ESTIMATE; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; OLIGODENDROGLIOMA; PROGNOSIS; YOUNG ADULT;

EID: 77954720733     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop071     Document Type: Article

References (26)

1. Vallat AV, Poirier J, Gray F, Chatel M. Tumeurs du système nerveux central. Classifications histologiques et topographiques, épidé miologie. EMC Neurologie. 1997;17-205-A-10
2. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol. 2007;114(2):97-109
3. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer. 1997;79(7):1381-1393
4. Surawicz TS, Davis F, Freels S, Laws ER, Jr, Menck HR. Brain tumor survival: results from the National Cancer Data Base. J Neurooncol. 1998;40(2):151-160
5. Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg. 1998;88(1):1-10
6. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumors in adults. Lancet. 2003;361(9354):323-331
7. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64(6):479-489
8. Nakamura M, Shimada K, Ishida E, Nakase H, Konishi N. Genetic analysis to complement histopathological diagnosis of brain tumors. Histol Histopathol. 2007;22(3):327-335
9. Fuller GN, Hess KR, Rhee CH, et al. Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol. 2002;12(1):108-116
10. Nutt CL, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003;63(7):1602-1607
11. Caskey LS, Fuller GN, Bruner JM, et al. Toward a molecular classification of the gliomas: histopathology, molecular genetics, and gene expression profiling. Histol Histopathol. 2000;15(3):971-981
12. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24(18):2707-2714
13. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000;18(3):636-645
14. Bauman GS, Ino Y, Ueki K, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys. 2000;48(3):825-830
15. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res. 2001;7(4):839-845
16. Hoang-Xuan K, He J, Huguet S, et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology. 2001;57(7):1278-1281
17. Bissola L, Eoli M, Pollo B, et al. Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. Ann Neurol. 2002;52(6): 842-845
18. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90(19):1473-1479
19. Van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not OS in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24(18): 2715
20. Dehais C, Laigle-Donadey F, Marie Y, et al. Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer. 2006;107(8):1891-1897
21. InoY, ZlatescuMC, Sasaki H, et al. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg. 2000;92(6):983-990
22. Thiessen B, Maguire JA, McNeil K, Huntsman D, Martin MA, Horsman D. Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. J Neurooncol. 2003;64(3):271-278
23. Daumas-Duport C, Beuvon F,Varlet P, Fallet-Bianco C. Gliomas:WHOand Sainte-Anne Hospital classifications. Ann Pathol. 2000;20(5):413-428
24. Zlatescu MC, TehraniYazdi A, Sasaki H, et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res. 2001;61(18):6713-6715
25. von Deimling A, Fimmers R, Schmidt MC, et al. Comprehensive allelotype and genetic anaysis of 466 human nervous system tumors. J Neuropathol Exp Neurol. 2000;59(6):544-558
26. Sanson M, Leuraud P, Aguirre-Cruz L, et al. Analysis of loss of chromosome 10q, DMBT1 homozygous deletions, and PTEN mutations in oligodendrogliomas. J Neurosurg. 2002;97(6):1397-1401